Effect of VX-770, a Cystic Fibrosis Transmembrane Conductance (CFTR) Potentiator, on Bone Phenotypes in ADO2 Mice

被引：0
|
作者：
Alam, Imranul [1 ]
Gerard-ORiley, Rita [1 ]
Acton, Dena [1 ]
Hong, Jung Min [2 ]
Bruzzaniti, Angela [2 ]
Econs, Michael J. [1 ]
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Dent, Indianapolis, IN USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-171
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [21] Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation
    Bruscia, EM
    Price, JE
    Cheng, EC
    Weiner, S
    Caputo, C
    Ferreira, EC
    Egan, ME
    Krause, DS
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (08) : 2965 - 2970
  • [22] Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate
    Lin, Wen-Ying
    Sohma, Yoshiro
    Hwang, Tzyh-Chang
    MOLECULAR PHARMACOLOGY, 2016, 90 (03) : 275 - 285
  • [23] The effect of triple therapy cystic fibrosis transmembrane conductance regulator (CFTR) modulation on anxiety in people with cystic fibrosis
    O'Carroll, O.
    McKeown, C.
    Bell, J.
    Nicholson, T.
    Gallagher, C.
    McKone, E.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [24] Effect of Roflumilast, a non-selective PDE4 inhibitor, on Bone Phenotypes in ADO2 Mice
    Alam, Imranul
    Hardman, Sara
    Gerard-O'Riley, Rita
    Acton, Dena
    Hong, Jung
    Bruzzaniti, Angela
    Econs, Michael
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 290 - 291
  • [25] Structural Consequences of the 1,2,3-Triazole as an Amide Bioisostere in Analogues of the Cystic Fibrosis Drugs VX-809 and VX-770
    Doiron, Jake E.
    Le, Christina A.
    Bacsa, John
    Breton, Gary W.
    Martin, Kenneth L.
    Aller, Stephen G.
    Turlington, Mark L.
    CHEMMEDCHEM, 2020, 15 (18) : 1720 - 1730
  • [26] Incomplete rescue of cystic fibrosis transmembrane conductance regulator deficient mice by the human CFTR cDNA
    Rozmahel, R
    Gyomorey, K
    Plyte, S
    Nguyen, V
    Wilschanski, M
    Durie, P
    Bear, CE
    Tsui, LC
    HUMAN MOLECULAR GENETICS, 1997, 6 (07) : 1153 - 1162
  • [27] The cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in maturation stage ameloblasts, odontoblasts and bone cells
    Bronckers, Antonius
    Kalogeraki, Lida
    Jorna, Huub J. N.
    Wilke, Martina
    Bervoets, Theodore J.
    Lyaruu, Donacian M.
    Zandieh-Doulabi, Behrouz
    DenBesten, Pamela
    de Jonge, Hugo
    BONE, 2010, 46 (04) : 1188 - 1196
  • [28] ADENOVIRAL MEDIATED TRANSFER OF RECOMBINANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INTO THE BILIARY-TRACT OF CYSTIC-FIBROSIS MICE
    YANG, Y
    NUNES, FA
    WILSON, JM
    GASTROENTEROLOGY, 1994, 106 (04) : A1011 - A1011
  • [29] PHASE 2 SAFETY AND EFFICACY: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR REGIMEN VX-445/TEZACAFTOR(TEZ)/IVACAFTOR(IVA)
    Keating, D.
    Taylor-Cousar, J.
    Marigowda, G.
    Burr, L.
    Daines, C.
    Mall, M.
    Mckone, E.
    Ramsey, B.
    Rowe, S.
    Sass, L.
    Tullis, E.
    Mckee, C.
    Moskowitz, S.
    Robertson, S.
    Savage, J.
    Simard, C.
    Van Goor, F.
    Waltz, D.
    Xuan, F.
    Young, T.
    RESPIROLOGY, 2019, 24 : 67 - 67
  • [30] PHASE 2 SAFETY AND EFFICACY: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR REGIMEN VX-659/TEZACAFTOR(TEZ)/IVACAFTOR(IVA)
    Keating, D.
    Davies, J.
    Moskowitz, S.
    Brown, C.
    Horsley, A.
    Mall, M.
    McKone, E.
    Plant, B.
    Prais, D.
    Taylor-Cousar, J.
    Tullis, E.
    Ramsey, B.
    Uluer, A.
    McKee, C.
    Robertson, S.
    Shilling, R.
    Simard, C.
    Van Goor, F.
    Waltz, D.
    Xuan, F.
    Young, T.
    Rowe, S.
    RESPIROLOGY, 2019, 24 : 68 - 68
12345